Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here:

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


CHAMPIONS TACKLING MS - AWARDS Dinner, Honoring Aaron Boster, MD and Jon e. Glaser, DDS - now open for registration. Visit

Friday, March 31, 2017

Aaron Boster, MD Discusses How OCRELIZUMAB works in MS


Dr.Boster explains how OCRELIZUMAB works in #MS

Learn more from here: 
Click here to receive MS news via e-mail
MS Views and News is MAKING an IMPACT on those affected by Multiple Sclerosis


Anonymous said...

So if this new medicine is so good, why do I want to use Rebif any more? If it's the same cost, and it's better, I would rather have two IV treatments. Aren't rebif et al. about the same cost?

Look at this comparison of costs:

Anonymous said...

You would want to stay on Rebif, as I am going to stay on Copaxone, because Rebif and Copaxone have been proven to be effective if they are used as directed and have less dangerous side effects than Ocrevus (ocrelizumab).